Published in J Natl Cancer Inst on November 27, 2007
The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer (2012) 4.72
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A (2010) 3.16
Relationship between male pattern baldness and the risk of aggressive prostate cancer: an analysis of the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. J Clin Oncol (2014) 2.12
Obesity and prostate cancer: weighing the evidence. Eur Urol (2012) 2.01
Notch-1 stimulates survival of lung adenocarcinoma cells during hypoxia by activating the IGF-1R pathway. Oncogene (2010) 1.70
Potential applications for biguanides in oncology. J Clin Invest (2013) 1.63
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2010) 1.62
Survival advantage observed with the use of metformin in patients with type II diabetes and colorectal cancer. Br J Cancer (2012) 1.61
Is there a role for carbohydrate restriction in the treatment and prevention of cancer? Nutr Metab (Lond) (2011) 1.35
The effects of varying dietary carbohydrate and fat content on survival in a murine LNCaP prostate cancer xenograft model. Cancer Prev Res (Phila) (2009) 1.13
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02. J Clin Oncol (2008) 1.11
Inhibition of the insulin-like growth factor-1 receptor (IGF1R) tyrosine kinase as a novel cancer therapy approach. J Med Chem (2009) 1.10
Low-carbohydrate diets and prostate cancer: how low is "low enough"? Cancer Prev Res (Phila) (2010) 0.94
Statin use as a moderator of metformin effect on risk for prostate cancer among type 2 diabetic patients. Diabetes Care (2012) 0.94
Dietary and pharmacological modification of the insulin/IGF-1 system: exploiting the full repertoire against cancer. Oncogenesis (2016) 0.93
The effect of carbohydrate restriction on prostate cancer tumor growth in a castrate mouse xenograft model. Prostate (2012) 0.90
Inhibition of Neuroblastoma Tumor Growth by Ketogenic Diet and/or Calorie Restriction in a CD1-Nu Mouse Model. PLoS One (2015) 0.89
Effect of isocaloric low fat diet on prostate cancer xenograft progression in a hormone deprivation model. J Urol (2010) 0.88
The natural compound Guttiferone F sensitizes prostate cancer to starvation induced apoptosis via calcium and JNK elevation. BMC Cancer (2015) 0.87
The impact of cow's milk-mediated mTORC1-signaling in the initiation and progression of prostate cancer. Nutr Metab (Lond) (2012) 0.81
Elevated insulin and insulin resistance are associated with the advanced pathological stage of prostate cancer in Korean population. J Korean Med Sci (2012) 0.81
Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer (2015) 0.80
Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation. Neuro Oncol (2015) 0.80
The emerging role of obesity, diet and lipid metabolism in prostate cancer. Future Oncol (2016) 0.79
Diabetes and its link with cancer: providing the fuel and spark to launch an aggressive growth regime. Biomed Res Int (2015) 0.79
A study of caloric restriction versus standard diet in overweight men with newly diagnosed prostate cancer: a randomized controlled trial. Prostate (2013) 0.79
Proinflammatory cytokines in prostate cancer development and progression promoted by high-fat diet. Biomed Res Int (2015) 0.77
Diabetes and mortality in patients with prostate cancer: a meta-analysis. Springerplus (2016) 0.77
Role of diet in prostate cancer: the epigenetic link. Oncogene (2014) 0.76
Interactions of the Insulin-Like Growth Factor Axis and Vitamin D in Prostate Cancer Risk in the Prostate Cancer Prevention Trial. Nutrients (2017) 0.75
Evidence suggesting that obesity prevention measures may improve prostate cancer outcomes using data from a prospective randomized trial. Prostate Cancer (2014) 0.75
Fortifying the Treatment of Prostate Cancer with Physical Activity. Prostate Cancer (2016) 0.75
The combination of serum insulin, osteopontin, and hepatocyte growth factor predicts time to castration-resistant progression in androgen dependent metastatic prostate cancer- an exploratory study. BMC Cancer (2016) 0.75
Highlights of the university of toronto urology update 2014. Can Urol Assoc J (2015) 0.75
Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res (2006) 6.99
Diabetes and cancer: a consensus report. Diabetes Care (2010) 6.71
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2010) 6.01
Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res (2007) 5.45
Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol (2012) 4.24
Impact of androgen deprivation therapy on cardiovascular disease and diabetes. J Clin Oncol (2009) 4.07
Diabetes and cancer: a consensus report. CA Cancer J Clin (2010) 3.95
Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol (2011) 3.75
Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: a long-term survival analysis. Lancet Oncol (2008) 3.62
Impact of 5α-reductase inhibitors on men followed by active surveillance for prostate cancer. Eur Urol (2010) 3.41
Active surveillance for early-stage prostate cancer: review of the current literature. Cancer (2008) 3.18
eIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc Natl Acad Sci U S A (2010) 3.13
Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst (2002) 3.03
Designing the Selenium and Vitamin E Cancer Prevention Trial (SELECT). J Natl Cancer Inst (2005) 2.99
Expression of TMPRSS2:ERG gene fusion in prostate cancer cells is an important prognostic factor for cancer progression. Cancer Biol Ther (2007) 2.97
The eEF2 kinase confers resistance to nutrient deprivation by blocking translation elongation. Cell (2013) 2.74
The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res (2008) 2.70
Metformin improves healthspan and lifespan in mice. Nat Commun (2013) 2.68
A new and highly prognostic system to discern T1 bladder cancer substage. Eur Urol (2011) 2.68
Therapeutic options following orchiectomy for stage I seminoma. Oncology (Williston Park) (2009) 2.67
A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells. Nat Med (2011) 2.54
Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol (2013) 2.53
Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival. Cancer Res (2008) 2.37
Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med (2008) 2.33
Insulin-like growth factor-I, IGF-binding protein-3, and mammographic breast density. Cancer Epidemiol Biomarkers Prev (2005) 2.28
Nutritional predictors of insulin-like growth factor I and their relationships to cancer in men. Cancer Epidemiol Biomarkers Prev (2003) 2.26
Evidence for a biopsy derived grade artifact among larger prostate glands. J Urol (2006) 2.23
A prospective study of plasma C-peptide and colorectal cancer risk in men. J Natl Cancer Inst (2004) 2.22
Prospective multi-institutional study evaluating the performance of prostate cancer risk calculators. J Clin Oncol (2011) 2.21
Electrostatic control of ions and molecules in nanofluidic transistors. Nano Lett (2005) 2.21
Long-term follow-up of T1 high-grade bladder cancer after intravesical bacille Calmette-Guérin treatment. BJU Int (2010) 2.14
Assessing individual risk for prostate cancer. J Clin Oncol (2007) 2.13
Pharmacological approaches to reducing the risk of prostate cancer. Eur Urol (2009) 2.09
Longer wait times increase overall mortality in patients with bladder cancer. J Urol (2009) 2.05
Controlled growth of Si nanowire arrays for device integration. Nano Lett (2005) 2.02
Metformin attenuates the stimulatory effect of a high-energy diet on in vivo LLC1 carcinoma growth. Endocr Relat Cancer (2008) 1.96
mTORC1 controls mitochondrial activity and biogenesis through 4E-BP-dependent translational regulation. Cell Metab (2013) 1.91
Akt phosphorylates the Y-box binding protein 1 at Ser102 located in the cold shock domain and affects the anchorage-independent growth of breast cancer cells. Oncogene (2005) 1.89
Fracture types and risk factors in men with prostate cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol (2010) 1.87
Genetic polymorphisms of the vitamin D binding protein and plasma concentrations of 25-hydroxyvitamin D in premenopausal women. Am J Clin Nutr (2008) 1.80
Is there an optimal comorbidity index for prostate cancer? Cancer (2008) 1.80
Health information quality on the internet in urological oncology: a multilingual longitudinal evaluation. Urology (2009) 1.78
Single-cell proteomic chip for profiling intracellular signaling pathways in single tumor cells. Proc Natl Acad Sci U S A (2011) 1.76
Plasma insulin-like growth factors, insulin-like binding protein-3, and outcome in metastatic colorectal cancer: results from intergroup trial N9741. Clin Cancer Res (2008) 1.76
Interobserver variability between expert urologic pathologists for extraprostatic extension and surgical margin status in radical prostatectomy specimens. Am J Surg Pathol (2008) 1.72
Regulation of cyclin dependent kinase 6 by microRNA 124 in medulloblastoma. J Neurooncol (2008) 1.72
Elevated bone turnover predicts for bone metastasis in postmenopausal breast cancer: results of NCIC CTG MA.14. J Clin Oncol (2011) 1.66
Population based study of long-term rates of surgery for urinary incontinence after radical prostatectomy for prostate cancer. J Urol (2012) 1.66
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol (2008) 1.64
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer Prev Res (Phila) (2010) 1.62
Metformin blocks the stimulative effect of a high-energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid synthase. Endocr Relat Cancer (2010) 1.61
Insulin receptor expression by human prostate cancers. Prostate (2009) 1.57
Population based survival data on urachal tumors. J Urol (2006) 1.55
Pathological, oncologic and functional outcomes of radical prostatectomy following active surveillance. J Urol (2013) 1.54
Optimal management of high-risk T1G3 bladder cancer: a decision analysis. PLoS Med (2007) 1.53
Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis (2012) 1.52
Higher surgeon and hospital volume improves long-term survival after radical cystectomy. Cancer (2013) 1.52
Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer. Cancer (2009) 1.50
Effects of biological reactions and modifications on conductance of nanofluidic channels. Nano Lett (2005) 1.50
IGF-1, IGFBP-1, and IGFBP-3 polymorphisms predict circulating IGF levels but not breast cancer risk: findings from the Breast and Prostate Cancer Cohort Consortium (BPC3). PLoS One (2008) 1.50
Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel. Clin Cancer Res (2002) 1.48
Nanotopography influences adhesion, spreading, and self-renewal of human embryonic stem cells. ACS Nano (2012) 1.47
Measurement of peri-prostatic fat thickness using transrectal ultrasonography (TRUS): a new risk factor for prostate cancer. BJU Int (2012) 1.46
Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int (2009) 1.46
Nephrogenic adenoma in the augmented bladder. J Urol (2011) 1.46
Impact of androgen-deprivation therapy on physical function and quality of life in men with nonmetastatic prostate cancer. J Clin Oncol (2010) 1.45
Antiarrhythmic effect mediated by κ-opioid receptor is associated with Cx43 stabilization. Crit Care Med (2010) 1.44
Distinct perturbation of the translatome by the antidiabetic drug metformin. Proc Natl Acad Sci U S A (2012) 1.43
Demographic analysis: an update of randomized controlled studies in prostatic oncology. Can Urol Assoc J (2011) 1.42
Molecular mechanisms underlying IGF-I-induced attenuation of the growth-inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. Int J Cancer (2004) 1.42
The involvement of AMPA-ERK1/2-BDNF pathway in the mechanism of new antidepressant action of prokinetic meranzin hydrate. Amino Acids (2012) 1.41
Radical prostatectomy in obese patients: Improved surgical outcomes in recent years. Int J Urol (2010) 1.41
Metformin and the incidence of prostate cancer in patients with type 2 diabetes. Cancer Epidemiol Biomarkers Prev (2010) 1.39
Utility of incorporating genetic variants for the early detection of prostate cancer. Clin Cancer Res (2009) 1.39
Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res (2009) 1.37
Associations between time spent sitting and cancer-related biomarkers in postmenopausal women: an exploration of effect modifiers. Cancer Causes Control (2014) 1.37
Clinical predictors of Gleason score upgrading: implications for patients considering watchful waiting, active surveillance, or brachytherapy. Cancer (2007) 1.35
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men. Cancer Res (2003) 1.31
MicroRNA 128a increases intracellular ROS level by targeting Bmi-1 and inhibits medulloblastoma cancer cell growth by promoting senescence. PLoS One (2010) 1.31
Is there age bias in the treatment of localized prostate carcinoma? Cancer (2004) 1.29
Inactivation of DNA-dependent protein kinase leads to spindle disruption and mitotic catastrophe with attenuated checkpoint protein 2 Phosphorylation in response to DNA damage. Cancer Res (2010) 1.28
Insulin increases de novo steroidogenesis in prostate cancer cells. Cancer Res (2011) 1.28
Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol (2011) 1.27
Vitamin D and calcium intakes from food or supplements and mammographic breast density. Cancer Epidemiol Biomarkers Prev (2005) 1.27
PTEN losses exhibit heterogeneity in multifocal prostatic adenocarcinoma and are associated with higher Gleason grade. Mod Pathol (2012) 1.26
Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. Int J Cancer (2011) 1.25
Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes. Breast Cancer Res (2008) 1.25
Synchronized seasonal variations of mammographic breast density and plasma 25-hydroxyvitamin d. Cancer Epidemiol Biomarkers Prev (2007) 1.24
Serum insulin-like growth factor (IGF) and IGF-binding protein levels and risk of lung cancer: a case-control study nested in the beta-Carotene and Retinol Efficacy Trial Cohort. Cancer Epidemiol Biomarkers Prev (2002) 1.23
Insulin-like growth factor-(IGF)-axis, inflammation, and glucose intolerance among older adults. Growth Horm IGF Res (2007) 1.23
Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res (2005) 1.22
Protein signaling networks from single cell fluctuations and information theory profiling. Biophys J (2011) 1.21
Nanowire substrate-based laser scanning cytometry for quantitation of circulating tumor cells. Nano Lett (2012) 1.19
Mammary-specific deletion of parathyroid hormone-related protein preserves bone mass during lactation. J Clin Invest (2003) 1.18
A study of high-dose oral silybin-phytosome followed by prostatectomy in patients with localized prostate cancer. Prostate (2010) 1.18
Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells. Med Sci Monit (2002) 1.18
C-reactive protein concentrations and subsequent ovarian cancer risk. Obstet Gynecol (2007) 1.17
Surgical margin status among men with organ-confined (pT2) prostate cancer: a population-based study. Can Urol Assoc J (2011) 1.17
Comprehensive analysis of common genetic variation in 61 genes related to steroid hormone and insulin-like growth factor-I metabolism and breast cancer risk in the NCI breast and prostate cancer cohort consortium. Hum Mol Genet (2010) 1.16